- Design
- phase 3, multicentre, open-label, randomised trial; prespecified interim analysis
- Population
- 451 patients with small-cell lung cancer progressing after first-line platinum-based therapy
- Primary outcome
- overall survival
- Effect
- median 13.3 vs 9.4 months, stratified hazard ratio 0.46 (95% CI 0.35-0.62), P<0.001
Relapsed small-cell lung cancer after platinum has had topotecan as its standard for two decades, with poor response and considerable toxicity. In this phase 3, multicentre, open-label trial, 451 patients progressing after first-line platinum were randomised 1:1 to tambotatug pelitecan, an antibody-drug conjugate directed at B7-H3, or to topotecan. This is a prespecified interim analysis.
Median overall survival was 13.3 months against 9.4 months, with a stratified hazard ratio for death of 0.46 (95% CI 0.35 to 0.62, P<0.001). Progression-free survival was 7.4 months against 2.8 (hazard ratio 0.29, 95% CI 0.23 to 0.37, P<0.001). Confirmed objective response occurred in 59.1% against 9.7%. Grade 3 or higher adverse events were less common with the conjugate, 55.4% against 77.9%.
An efficacy gain of this size accompanied by less high-grade toxicity is unusual, and in a disease that has resisted improvement for a generation it is the most consequential oncology result of the day. Two cautions belong in the reading. It is an open-label interim analysis, so the survival estimate will move as follow-up matures, and the upper confidence bound on median survival could not yet be estimated. And it is a comparison against topotecan - a low bar, chosen correctly as the standard of care, but a standard nobody defends. Availability and cost will determine whether this reaches Indian patients, and neither is addressed by the trial.
- For relapsed small-cell lung cancer after platinum, this is now the strongest randomised evidence available.
- Quote the medians - 13.3 against 9.4 months - rather than the hazard ratio, when discussing with patients.
- Note the lower grade 3 or higher toxicity: this is not the usual trade of efficacy against tolerability.
- Treat the survival figure as provisional; this is a prespecified interim analysis with immature follow-up.
- Access, not evidence, will be the constraint in most Indian centres; there is no data here on cost or availability.
Why it matters
It is the first clear survival advance over topotecan in relapsed small-cell lung cancer in two decades, and it came with less high-grade toxicity rather than more.
Don't overread it
This is an open-label prespecified interim analysis: survival estimates are immature, and the comparator, though standard, is a weak one.
The statistics, in plain English
A hazard ratio of 0.46 for death means the rate of dying at any moment was roughly halved, and the interval (0.35 to 0.62) sits well clear of 1.0. The progression-free survival ratio of 0.29 is even more striking but should not be added to the survival claim - it partly reflects how poorly topotecan controls disease. That the upper bound of median survival 'could not be estimated' simply means too many patients were still alive to calculate it, which is itself a favourable sign but also a reminder the estimate is immature.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for oncology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free